Taken together, our data suggest that an Hh signal is required for the re-expression of KRAS, reactivation of ERK, and sonidegib blocks the generation of acquired resistance in cancer cells after treatment with a KRASG12C inhibitor. This evidence concerns the gene KRAS and cancer.